Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionChange Path, LLC
Latest Disclosed Ownership29,421 shares
Latest Disclosed Value $ 1,901,479
Change Path, LLC reports 131.64% increase in ownership of HALO / Halozyme Therapeutics, Inc.

On May 15, 2026 - Change Path, LLC filed a 13F-HR form disclosing ownership of 29,421 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $1,901,479 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 12,701 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of 131.64% during the quarter. The current value of the position is $2,054,174 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 29,421 16,720 131.64 1,901 122.60 0.0405
2026-02-13 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 12,701 -1,096 -7.94 855 -15.53 0.0207
2025-11-13 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 13,797 -2,762 -16.68 1,012 17.42 0.0247
2025-08-12 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 16,559 -1,097 -6.21 861 -23.53 0.0226
2025-05-14 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 17,656 -727 -3.95 1,127 28.25 0.0337
2025-02-13 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 18,383 294 1.63 879 -15.17 0.0269
2024-11-13 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 18,089 18,089 1,035 0.0352
2023-05-15 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -4,744 -100.00 0 -100.00
2023-02-15 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 4,744 4,744 270 0.0149
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.